For Quest and LabCorp, The Story is “Molecular”

CEO SUMMARY: Wall Street likes the potential of molecular diagnostics to infuse new revenues and operating profits into the laboratory industry. That is one reason Quest Diagnostics Incorporated and Laboratory Corporation of America are assertively seeking exclusive access to new molecular technologies. The latest such deal is Quest Diagnostics’ $42.8 million agreement with Ciphergen Biosystems. …

For Quest and LabCorp, The Story is “Molecular” Read More »

To access this post, you must purchase The Dark Report.

For Quest and LabCorp, The Story is “Molecular”

Both lab companies racing to lock up most promising molecular technologies

Comments

TABLE OF CONTENTS

Need A Group Membership? Company Discounts are Available!

You are reading premium content from The Dark Report, your primary resource for running an efficient and profitable laboratory.

Get Unlimited Access to The Dark Report absolutely FREE!

You have read 0 of 1 of your complimentary articles this month

You have read 0 of 1 of your complimentary articles this month